evipedia.ai
← Back

Magnesium Bisglycinate for Health & Longevity

Evidence Review created on 08/23/2026 using AI4L / Opus 5

Also known as: Magnesium Glycinate, Magnesium Diglycinate, Magnesium Bis-Glycinate, Bisglycinate Chelate

Motivation

Magnesium bisglycinate is a magnesium salt in which each magnesium atom is bound to two molecules of the amino acid glycine. That bound structure is marketed as being gentler on the digestive tract and better absorbed than cheaper mineral forms such as magnesium oxide, and it has made bisglycinate one of the most widely sold magnesium products on the shelf.

Magnesium itself takes part in hundreds of enzyme reactions covering energy production, nerve and muscle function, and blood pressure control. Diet surveys across industrialised countries repeatedly find intakes below recommended amounts, and low magnesium levels travel alongside a long list of chronic conditions. Whether swallowing a bound form of the mineral changes any of that is contested.

This review examines what the evidence shows about magnesium bisglycinate: how much elemental mineral it actually delivers, whether its absorption and tolerance advantages survive measurement, which health outcomes shift when magnesium is supplemented and by how much, how closely the marketing claims track the trial data, and how the picture differs for someone already eating well.

Benefits - Risks - Protocol - Conclusion

Sources that give a high-level, substantive overview of magnesium bisglycinate and how it compares to other magnesium forms.

Content from five of the six priority platforms is listed above. Lifespan.io’s magnesium coverage consists of a reference-style topic entry that catalogues the mineral rather than discussing it, plus short news write-ups of individual studies; neither gives a high-level overview of this form, so neither qualifies here.

Grokipedia

  • Magnesium glycinate

    Consolidates the chemistry, elemental magnesium fraction, absorption claims and marketed uses of this specific chelate in one entry, and flags where consumer marketing runs ahead of trial evidence.

Examine

  • Magnesium

    Graded outcome database spanning 35 conditions plus dosage, safety and interaction sections; treats bisglycinate as one of several well-absorbed organic forms rather than giving it a separate entry.

ConsumerLab

  • Magnesium Supplements Review

    Independent laboratory testing of marketed products, including two rejected for apparently substituting cheaper oxide for labelled glycinate, plus reporting on lead findings and cost per 200 mg magnesium.

Systematic Reviews

The pooled evidence for oral magnesium supplementation, covering the outcomes most often claimed for the bisglycinate form and the harms recorded alongside them.

The principal trade-off — gastrointestinal intolerance — is represented by the Cochrane harms analysis above, and the claimed effects by the blood pressure, glucose and insomnia reviews. No systematic review has yet pooled absorption or tolerability data for magnesium bisglycinate as a form distinct from other organic magnesium salts.

Mechanism of Action

Magnesium is the second most abundant positively charged particle inside human cells and acts as a cofactor in more than 600 enzyme reactions, most of them involving the transfer of the cell’s energy currency adenosine triphosphate (ATP, the molecule cells use to store and spend energy), as described by Kröse & de Baaij. It blocks calcium entry into smooth muscle and blunts the excitatory NMDA (N-methyl-D-aspartate, a brain receptor that drives nerve excitation) receptor while supporting GABA (gamma-aminobutyric acid, the brain’s main calming signal) tone — the proposed route to lower blood pressure, easier sleep onset and reduced nerve excitability.

The bisglycinate form differs only in its carrier. Two glycine molecules ring the magnesium ion, leaving a neutral, fat-soluble complex that is thought to be taken up partly intact through intestinal peptide transporters rather than solely through the paracellular (between-cell) and TRPM6/TRPM7 (gut and kidney magnesium channel) routes; Schuette et al. inferred this from isotope tracing. A competing reading is that bisglycinate is simply more soluble and less osmotically active, so it draws less water into the bowel and leaves more time for ordinary absorption — no dipeptide pathway required.

Key pharmacological properties: roughly 20–50% of an oral dose is absorbed, the fraction falling as dose rises; the glycine is metabolised as an ordinary amino acid; magnesium undergoes no liver metabolism and no cytochrome P450 (the liver’s main drug-processing enzyme family) handling; and clearance is renal, with a plasma half-life of a few hours but tissue turnover measured in weeks.

Historical Context & Evolution

Magnesium salts entered medicine as purgatives. Epsom salt (magnesium sulfate) was drawn from mineral springs in seventeenth-century England and used as a laxative and bathing salt; magnesium hydroxide followed as an antacid. The first serious therapeutic use came in obstetrics, where injected magnesium sulfate was adopted in the 1920s to control the seizures of eclampsia (a seizure emergency of late pregnancy) — still its strongest indication today.

Amino acid chelates were a later, commercial development. Mineral chemists in the 1960s and 1970s argued that binding a mineral to amino acids would let it cross the gut wall by peptide routes rather than competing for ion channels, and magnesium diglycinate was formulated on that premise. The claim was tested directly in 1994, when Schuette et al. gave isotope-labelled diglycinate and oxide to twelve patients with ileal resection (surgical removal of part of the small intestine): across the whole group absorption did not differ, but in the four with the most impaired absorption the chelate roughly doubled uptake, appeared in blood earlier and was better tolerated.

Interest then shifted from repletion to prevention. Population work linking low magnesium intake to cardiovascular disease and diabetes, plus the argument from DiNicolantonio et al. that widespread subclinical deficiency is invisible to routine blood tests, moved magnesium from a treatment for a diagnosed deficit to a general-purpose supplement. Whether outcome data justify that shift, rather than mechanism and marketing, remains open; the first placebo-controlled trial of bisglycinate specifically was published only in 2025.

Expected Benefits

For a health-conscious adult already eating a reasonable diet, the signal here is narrower than the marketing suggests: the outcomes that move reliably are those where magnesium status was low to begin with, or where a drug-treated condition is already present.

High 🟩 🟩 🟩

Blood Pressure Reduction

Magnesium relaxes vascular smooth muscle by competing with calcium and supporting nitric oxide. Argeros et al. pooled 38 randomised controlled trials (RCTs, trials with random assignment to treatment or placebo) in 2,709 people; Zhang et al. agrees. The average effect is small but concentrates in people already on blood-pressure medication and those with low magnesium, and does not reach significance in normal pressure. Heterogeneity is high and no dose-response was found.

Magnitude: −2.81 mmHg systolic and −2.05 mmHg diastolic overall (95% confidence interval −4.32 to −1.29 and −3.23 to −0.88); −7.68 mmHg systolic in treated hypertensive participants and −5.97 mmHg in those with low magnesium, at a median 365 mg/day for 12 weeks.

Improved Glucose Control and Insulin Sensitivity

Magnesium is a cofactor for the insulin receptor’s signalling cascade, and low status is common in insulin resistance. Veronese et al. pooled double-blind RCTs and found lower fasting glucose in people with diabetes plus improved insulin-sensitivity markers in those at high risk; a dose-response meta-analysis by Asbaghi et al. reaches the same conclusion in type 2 diabetes. Trials in metabolically healthy participants show little. The effect therefore reads as correction of a deficit rather than enhancement of normal function.

Magnitude: In type 2 diabetes the dose-response analysis estimates glycated haemoglobin −0.73% at 500 mg/day (95% confidence interval −1.25 to −0.22) and fasting blood sugar −15.58 mg/dL at 24 weeks (95% confidence interval −24.67 to −6.49); two-hour post-load glucose and insulin-sensitivity markers also improve in those at high risk.

Reduced Insomnia Severity

This is the one outcome with direct bisglycinate evidence. Schuster et al. randomised 155 adults with self-reported poor sleep to 250 mg elemental magnesium as bisglycinate or placebo for four weeks, with the Insomnia Severity Index as the primary endpoint. The pooled analysis by Mah & Pitre of three earlier trials in older adults points the same way on sleep onset. Effects are small, the trials carry moderate-to-high bias risk, and gains were largest in participants with the lowest dietary magnesium intake.

Magnitude: Insomnia Severity Index fell 3.9 points on bisglycinate (95% confidence interval 2.0 to 5.8) versus 2.3 on placebo (0.4 to 4.1) over four weeks — a 1.6-point between-group difference, p = 0.049, Cohen’s d 0.20 (a standardised measure of effect size, where 0.2 counts as small); pooled trials of mixed magnesium forms shortened time to fall asleep by about 17 minutes.

Reduced Depressive Symptoms

Magnesium modulates NMDA receptor activity, the same target as several rapid-acting antidepressants, which is the mechanistic case for an antidepressant effect. Moabedi et al. pooled seven RCTs in adults with diagnosed depressive disorder and found a large reduction in depression scores. The total sample is only 325 people across small studies of varying magnesium forms and durations, so the pooled estimate is fragile; a review of magnesium across mental disorders by Botturi et al. is more cautious.

Magnitude: Standardised mean difference −0.92 (a measure of effect size that lets trials using different depression scales be pooled; 95% confidence interval −1.44 to −0.40) across seven trials totalling 325 adults — a large effect drawn from small studies.

Fewer Migraine Attacks

Magnesium is thought to raise the threshold for cortical spreading depression, the wave of neuronal activity that initiates migraine aura. The dose-response meta-analysis by Talandashti et al. compared several supplements head to head against placebo and found magnesium reduced attack frequency, severity and monthly migraine days. The trials used a range of magnesium salts, mostly citrate and oxide rather than bisglycinate, and doses sat at the upper end of the supplemental range.

Magnitude: About 2.5 fewer attacks per month, 1.66 fewer monthly migraine days, and a 0.88-point fall in attack severity versus control across the pooled trials.

Medium 🟩 🟩

Repletion of Low Magnesium Status with Better Tolerability than Oxide

The specific selling point of bisglycinate is delivering magnesium without the osmotic laxative effect that limits oxide and citrate dosing. Schuette et al. tested this directly with stable-isotope tracing in a randomised crossover of twelve patients with ileal resection: the two forms were equivalent overall, but the chelate outperformed oxide in the worst absorbers and was better tolerated by everyone. The systematic review by Pardo et al. places organic salts generally above inorganic ones. The direct evidence rests on one small trial.

Magnitude: In the patients whose oxide absorption was most impaired, bisglycinate delivered 23.5% absorption versus 11.8% for oxide from a 100 mg dose; across the whole group the two did not differ (23.5% versus 22.8%), though peak blood levels arrived 3.2 hours earlier on the chelate.

Enhanced Vitamin D Status When Taken Together

Every enzyme that converts vitamin D to its active form requires magnesium, a dependency set out by Uwitonze & Razzaque. Cheung et al. tested it in a 12-week three-arm RCT in 95 adults with overweight or obesity, using magnesium glycinate specifically alongside vitamin D. The combination raised vitamin D levels more than vitamin D alone. This is a single trial in one population, and a companion analysis by Dall et al. found no effect on bone-turnover or glycaemic markers.

Magnitude: Serum 25-hydroxyvitamin D rose 6.3 ± 8.36 ng/mL over 12 weeks on 360 mg magnesium glycinate plus 1,000 IU (international units) of vitamin D daily, exceeding vitamin D alone; systolic pressure fell 7.5 mmHg in the subgroup starting above 132 mmHg.

Low 🟩

Lower Systemic Inflammation ⚠️ Conflicted

Veronese et al. pooled 17 RCTs in 889 participants and found C-reactive protein (CRP, a general blood marker of inflammation) fell and nitric oxide rose; Talebi et al. pooled 18 trials and found no significant change in CRP. Net reading: the inflammation signal is unreliable.

Magnitude: One meta-analysis reports a standardised reduction in C-reactive protein, the other a non-significant −0.49 mg/L (95% confidence interval −1.72 to 0.75); the pooled literature gives no agreed outcome figure.

Reduced Subjective Anxiety ⚠️ Conflicted

Boyle et al. reviewed 18 magnesium studies: some anxiety-prone samples improved, others did not, with poor trial quality throughout and no usable pooled estimate. The bisglycinate trial by Schuster et al. found no change in anxiety or stress scores. Net reading: any anxiety effect is unproven.

Magnitude: Four of eight trials in anxiety-vulnerable samples reported benefit and four did not; the review reports no pooled effect size because measures and quality varied too widely.

Reduced Muscle Cramp Frequency ⚠️ Conflicted

The Cochrane review by Garrison et al. tested magnesium across 11 trials in 735 people. In older adults with idiopathic night cramps the result was a clear null; pregnancy trials disagree. Net reading: the cramp claim fails for the population most likely to buy it.

Magnitude: −0.18 cramps per week versus placebo at four weeks (95% confidence interval −0.84 to 0.49) in idiopathic cramps, with no difference in intensity or duration; pregnancy trials report conflicting results.

Higher Hip Bone Mineral Density

Groenendijk et al. pooled cohort and cross-sectional data in adults aged 60 and over: higher magnesium intake tracked with higher hip and femoral neck bone density. All the evidence is observational, no intervention trial exists, and no fracture outcomes were available.

Magnitude: Pooled regression coefficient 0.03 (95% confidence interval 0.01 to 0.06) for hip bone mineral density per unit of magnesium intake across four studies; no fracture data exist.

Lower All-Cause Mortality Signal ⚠️ Conflicted

Bagheri et al. pooled 19 cohorts covering 1.17 million people: dietary magnesium tracked with lower all-cause and cancer mortality, while supplemental and total intake showed no association. Fang et al. found the same dietary signal but did not assess supplements. Net reading: magnesium-rich diets, not capsules, carry the mortality signal.

Magnitude: Each additional 100 mg/day of dietary magnesium was associated with 6% lower all-cause mortality and 5% lower cancer mortality; supplemental magnesium intake showed no association with any mortality outcome.

Speculative 🟨

Slower Vascular Calcification

Villa-Bellosta showed dietary magnesium reduced vascular smooth-muscle calcification and extended lifespan in a mouse model of progeria (a rare rapid-ageing disease). The basis is animal work only; no human trial has tested calcification with bisglycinate.

Brain Magnesium Delivery for Cognition

Marketing implies bisglycinate raises brain magnesium. In the rodent comparison by Ates et al., glycinate did not while acetyl taurate did. The basis is animal tissue data only; no human cognitive trial exists.

Benefit-Modifying Factors

  • Baseline magnesium status: The largest single modifier. Blood-pressure, sleep and glucose benefits concentrate in people with low magnesium or low dietary intake; the bisglycinate sleep trial found its strongest responders among participants reporting the lowest dietary magnesium.

  • Genetic variation in magnesium transport: Variants in TRPM6, TRPM7 and CLDN16 (a kidney tight-junction protein) alter absorption and retention. Rare severe variants cause lifelong wasting; no supplement trial has stratified on the common ones.

  • Pre-existing metabolic and cardiovascular conditions: Benefit is much larger in people already treated for high blood pressure, in type 2 diabetes and in insulin resistance. Metabolically healthy participants show little to no change on the same doses.

  • Sex-based differences: Women have lower absolute magnesium requirements but higher reported deficiency prevalence, and premenstrual symptom trials are the largest female-specific evidence base. Sex-stratified effects on blood pressure and glucose have not been separately reported in the major meta-analyses.

  • Age-related considerations: Absorption efficiency declines and kidney conservation weakens with age, and older adults take more magnesium-depleting drugs. Adults at the older end of the target range therefore start lower and respond more; the insomnia meta-analysis was conducted entirely in this group.

Potential Risks & Side Effects

For a healthy adult with intact kidney function the risk profile is narrow and dose-driven; the serious hazards belong to specific populations rather than to the compound itself.

High 🟥 🟥 🟥

Gastrointestinal Upset and Loose Stools

Unabsorbed magnesium holds water in the bowel, producing stool softening or diarrhoea. The Cochrane harms analysis by Garrison et al. pooled adverse events across trials of oral magnesium and found minor gastrointestinal events consistently more frequent than on placebo. Bisglycinate is the form least likely to cause this — more soluble and osmotically gentler than oxide or citrate — but the effect is not abolished. It is dose-related and reverses on dose reduction.

Magnitude: Minor adverse events, predominantly loose stools, occurred in 11% to 37% of magnesium recipients versus 10% to 14% of placebo recipients (risk ratio 1.51, 95% confidence interval 0.98 to 2.33, four trials, 254 participants); major events and withdrawals did not differ.

Medium 🟥 🟥

Hypermagnesemia with Impaired Kidney Function

Excess magnesium is cleared almost entirely by the kidneys, so failing filtration allows hypermagnesemia (dangerously high blood magnesium) to develop. Schelling documents a fatal case in unrecognised acute kidney failure, with bradycardia (an abnormally slow heart rate), heart attack and respiratory failure. Vermeulen & Vervloet review the chronic kidney disease literature and find controlled dosing safe in that population, which sharpens rather than removes the warning: the danger lies in high doses given without knowing filtration status.

Magnitude: Risk rises steeply once kidney filtration is impaired or supplemental intake exceeds roughly 1,000 mg daily; the human literature consists of case reports and small series and provides no incidence figure.

Reduced Absorption of Co-Administered Medications

Magnesium ions bind several drug classes in the gut and raise stomach pH, cutting their absorption. Nix et al. quantified this for ciprofloxacin with magnesium-aluminium antacids in a crossover study, and Mersebach et al. showed the same adsorption for levothyroxine. Most of the data come from magnesium antacids rather than bisglycinate, whose lower acid-neutralising capacity may make the interaction weaker — but chelation of the drug does not depend on pH, so the caution stands.

Magnitude: Ciprofloxacin relative bioavailability fell to 15.1% when antacid was taken 5–10 minutes before, 23.2% at two hours and 70% at four hours; dosing the antacid two hours after ciprofloxacin had no effect.

Low 🟥

Glycine Load at Higher Doses

Bisglycinate carries a large glycine load alongside the mineral: in the trial by Schuster et al., 250 mg elemental magnesium came with 1,523 mg glycine daily. Glycine is well tolerated at these levels, but part of any observed effect may be glycine rather than magnesium.

Magnitude: Roughly 6 mg of glycine accompanies every 1 mg of elemental magnesium, so 400 mg/day adds about 2,400 mg of glycine — below the 3,000 mg doses reported without adverse events by Bannai & Kawai, but with no controlled long-term data at any level.

Next-Day Sedation

Because bisglycinate is taken at night and glycine lowers core body temperature, residual drowsiness is plausible. The four-week trial by Schuster et al. measured daytime sleepiness directly and found no difference from placebo — a single trial with sleepiness as a secondary endpoint, so reassuring rather than conclusive.

Magnitude: Epworth Sleepiness Scale change was −2.0 on bisglycinate versus −1.8 on placebo over four weeks (p = 0.624, Cohen’s d 0.05); no trial has measured next-day drowsiness as a primary endpoint.

Speculative 🟨

Increased Bleeding Tendency

Laboratory work shows magnesium reduces platelet aggregation and clot formation. No clinical reports of bleeding from oral magnesium exist; the concern rests on in-vitro assays alone, with no human outcome data.

Consequences of Chronic High Glycine Exposure

Glycine acts as an inhibitory neurotransmitter and an NMDA co-agonist, so sustained high intake is theoretically active in the brain. No human outcome data cover years of bisglycinate-derived doses; the basis is mechanistic only.

Risk-Modifying Factors

  • Kidney function: The dominant modifier. Estimated glomerular filtration rate (eGFR, a calculated measure of how well the kidneys filter blood) below 60 mL/min/1.73 m² sharply raises accumulation risk, and acute kidney injury converts an ordinary dose into a dangerous one.

  • Baseline biomarker levels: Blood magnesium at the upper end of the reference range, or coexisting high calcium, signals reduced headroom. Low potassium or calcium that will not correct usually indicates magnesium depletion rather than a reason to stop.

  • Genetic variation: Loss-of-function variants in TRPM6 or CLDN16 cause renal magnesium wasting and raise the dose needed; gain-of-function states are not described. These variants are rare and are not routinely genotyped.

  • Pre-existing health conditions: Slow heart rate, second- or third-degree heart block, myasthenia gravis (an autoimmune disease causing muscle weakness) and bowel obstruction raise the consequence of high magnesium. Inflammatory bowel disease and constipation increase absorption or retention.

  • Sex-based differences: No sex difference in adverse-event rates has been reported. Women’s lower body mass and lower recommended intake mean a given dose delivers proportionally more, and pregnancy-associated cramp trials are the only female-specific safety dataset.

  • Age-related considerations: Kidney filtration falls roughly 1% per year after 40, so an unchanged dose delivers a rising internal exposure. Adults at the older end of the target range also take more concurrent medications and face more absorption interactions.

Key Interactions & Contraindications

  • Fluoroquinolone and tetracycline antibiotics — two widely used antibiotic families (ciprofloxacin, levofloxacin, doxycycline, minocycline): Caution. Magnesium chelates the antibiotic and can cut absorption to a fraction, risking treatment failure. Mitigation: taking the antibiotic at least two hours before, or four to six hours after, magnesium.

  • Levothyroxine and thyroid hormone: Caution. Adsorption in the gut lowers hormone absorption and can raise thyroid-stimulating hormone. Mitigation: separating by at least four hours, with thyroid function rechecked after starting magnesium.

  • Bisphosphonates — bone-density drugs (alendronate, risedronate, oral zoledronic acid): Caution. Divalent (two-charge) minerals sharply reduce absorption of an already poorly absorbed drug. Mitigation: dosing the bisphosphonate on waking, magnesium no sooner than two hours later.

  • Potassium-sparing diuretics — urine-increasing drugs that retain potassium (spironolactone, amiloride, eplerenone) — and ACE inhibitors (angiotensin-converting enzyme inhibitors, a blood-pressure drug class): Monitor. Both reduce magnesium excretion, so supplementation can push levels higher than intended. Mitigation: checking blood magnesium and potassium within 4–8 weeks.

  • Proton pump inhibitors — long-acting stomach-acid blockers (omeprazole, pantoprazole, esomeprazole): Monitor — an interaction in the opposite direction. Long-term use causes hypomagnesemia (low blood magnesium) that oral supplementation often fails to correct, as Gommers et al. describe. Mitigation: measuring rather than assuming repletion.

  • Over-the-counter antacids and laxatives containing magnesium or aluminium: Caution. These stack additional magnesium onto the supplemental dose and independently block drug absorption. Mitigation: counting their magnesium content toward the daily total.

  • Blood-pressure-lowering supplements (potassium, taurine, beetroot nitrate, hibiscus, omega-3 fatty acids): Additive. Combined use can lower pressure further than intended, particularly alongside prescribed antihypertensives. Mitigation: home monitoring during the first month of any addition.

  • Calming supplements with additive sedation (glycine, theanine, apigenin, valerian, melatonin): Additive. Bisglycinate already supplies substantial glycine, so stacking risks unintended morning sedation. Mitigation: introducing one agent at a time.

  • Zinc, iron and calcium at high single doses: Caution. Divalent minerals compete for shared intestinal transport, reducing uptake of each. Mitigation: separating high-dose zinc or iron from magnesium by two hours; calcium above 500 mg is the main competitor.

  • Alcohol and endurance training as non-drug interventions: Both increase urinary magnesium loss, raising requirements rather than causing toxicity. Mitigation: heavier drinkers and high-volume endurance athletes may need the upper end of the dose range.

Populations who should avoid Magnesium Bisglycinate:

  • Chronic kidney disease stage 4 or worse (eGFR below 30 mL/min/1.73 m²), or any acute kidney injury
  • Second- or third-degree heart block, or resting bradycardia below 50 beats per minute, without cardiology oversight
  • Myasthenia gravis, where raised magnesium worsens muscle weakness
  • Known bowel obstruction or severely slowed gut transit
  • Documented hypersensitivity to magnesium salts or to glycine

Risk Mitigation Strategies

  • Kidney function check before starting: A current eGFR above 60 mL/min/1.73 m² establishes that excess magnesium can be cleared, and removes the main route to the hypermagnesemia and cardiac conduction effects described above.

  • Low starting dose with slow titration: Protocols typically begin at 100–150 mg elemental magnesium at night and increase by 100 mg every one to two weeks toward 200–400 mg. Slow escalation keeps loose stools below the threshold that ends adherence.

  • Stool consistency as the dose ceiling: Softening of stool marks the point at which unabsorbed magnesium is drawing water into the bowel. Stepping back to the last comfortable dose prevents diarrhoea and the electrolyte loss it causes.

  • Timing separation from chelating medications: Taking fluoroquinolones, tetracyclines, levothyroxine and bisphosphonates at least two to four hours apart from magnesium avoids the absorption losses that cause antibiotic failure and thyroid destabilisation.

  • Total magnesium tallied across all sources: Antacids, laxatives, multivitamins and electrolyte powders often contain magnesium. Summing them keeps supplemental intake below roughly 350–400 mg/day and prevents inadvertent excess.

  • Electrolyte recheck at four to eight weeks on kidney-affecting drugs: Blood magnesium, potassium and creatinine at this interval catch accumulation early in the group most prone to it, before conduction or neuromuscular effects appear.

  • Single-agent introduction among calming supplements: Adding bisglycinate separately from glycine, theanine or melatonin isolates which agent causes any morning sedation, and prevents an unrecognised cumulative glycine load.

Therapeutic Protocol

  • Standard dose range: Chris Kresser sets total food-plus-supplement targets of roughly 500–655 mg/day; the trial literature clusters at 200–400 mg/day of supplemental elemental magnesium, and the bisglycinate sleep trial used 250 mg.

  • Reading the label correctly: Bisglycinate is roughly 10–14% elemental magnesium by mass, so a 1,000 mg product supplies only 100–140 mg of the mineral. Protocols specify the elemental figure, never the compound weight.

  • Competing approaches: Peter Attia combines a poorly absorbed form for bowel effect, a well-absorbed salt, and L-threonate for central effects; Andrew Huberman’s sleep protocol uses 200 mg bisglycinate alone; Rhonda Patrick splits a blend across day and night.

  • Timing: Taken 30–60 minutes before bed in the sleep trials, which is also when the glycine component is most useful. Daytime dosing suits those using magnesium for blood pressure or glucose rather than sleep.

  • Half-life and dosing frequency: Plasma half-life of an oral dose is a few hours, but tissue repletion takes weeks. Absorbed fraction falls as dose rises, so splitting anything above 200 mg into two doses is common practice.

  • Genetic considerations: No pharmacogenetic test guides magnesium dosing. Rare TRPM6 and CLDN16 variants causing renal wasting demand far higher doses, and are identified clinically by persistent hypomagnesemia rather than by genotyping.

  • Sex-based differences: Recommended intakes are lower for women (310–320 mg/day) than men (400–420 mg/day). No trial has demonstrated a sex difference in response to supplementation; premenstrual symptom protocols commonly use 200–360 mg daily.

  • Age-related considerations: Older adults absorb less and lose more, so the same target intake requires a higher supplemental dose. Against this, falling kidney filtration narrows the safety margin, making periodic measurement more important than dose escalation.

  • Baseline biomarkers guiding the dose: Low or low-normal blood magnesium, low red blood cell magnesium, or refractory low potassium argue for the upper dose range; mid-range values in a person eating magnesium-rich foods argue for the lower end or none.

  • Pre-existing conditions influencing response: Type 2 diabetes, treated hypertension, chronic proton pump inhibitor use, malabsorption and heavy alcohol intake all predict larger responses because they predict a starting deficit.

Discontinuation & Cycling

  • Intended duration: Framed as ongoing rather than a course. Magnesium is an essential nutrient with no storage buffer that persists off supplementation, so blood and tissue levels drift back toward dietary intake within weeks of stopping.

  • Withdrawal effects: None described. Stopping produces no rebound syndrome; symptoms that return — poor sleep, cramps, palpitations — reflect the reappearance of the original deficit rather than a withdrawal state.

  • Tapering: Not required pharmacologically. Abrupt cessation is uneventful. Some practitioners step down gradually purely to observe which symptoms return and at what point, as an informal test of whether the supplement was doing anything.

  • Cycling: No evidence supports cycling for efficacy. Magnesium shows no tolerance or receptor downregulation, and no trial has compared continuous with intermittent dosing. Periodic reassessment of need is a more defensible practice than scheduled breaks.

  • Reassessment trigger: A meaningful change in diet, kidney function or medication — particularly starting or stopping a proton pump inhibitor or diuretic — alters requirements enough to justify remeasuring rather than continuing the same dose indefinitely.

Sourcing and Quality

  • The elemental magnesium figure on the label: Labels may list compound weight, elemental weight or both. The elemental number is the only comparable one, and a product declaring “1,000 mg magnesium bisglycinate” typically supplies 100–140 mg of usable mineral.

  • Buffered blends and undisclosed oxide: Many low-cost “magnesium glycinate” products are buffered with magnesium oxide to raise the elemental figure cheaply. ConsumerLab rejected two products for apparently substituting oxide for the labelled form; a fully chelated product states so.

  • Third-party testing and batch certificates: Independent certification (USP, NSF, Informed Choice) or a batch certificate of analysis addresses both label accuracy and contamination. Testing groups have reported lead in some magnesium products, and cross-contamination with anabolic steroids has occurred historically.

  • Reputable brands: Products that have passed independent testing include Doctor’s Best, Pure Encapsulations, Thorne, NOW Foods, Life Extension and Klaire Labs. Albion and TRAACS designate specific licensed chelate raw materials rather than finished-brand quality.

  • Formulation and excipients: Capsules are preferable to gummies, which dilute the dose and add sugar. The bulk of the chelate means honest products need two to four capsules for a full dose; single-capsule “full dose” claims usually signal buffering.

Practical Considerations

  • Time to effect: Sleep and bowel effects appear within days. Blood pressure and glucose changes emerged over 8–12 weeks in the trials, and tissue repletion after genuine depletion takes several months of consistent intake.

  • Common pitfall — confusing compound and elemental weight: The most frequent error is taking a fraction of the intended dose because the label headline refers to compound weight. Comparing products on the elemental figure resolves it.

  • Common pitfall — expecting effects without a deficit: Every major benefit concentrates in people with low magnesium status or an existing treated condition. Metabolically healthy adults with magnesium-rich diets show the smallest changes on the same dose.

  • Common pitfall — timing against medications: Taking bisglycinate at bedtime alongside a bedtime thyroid or antibiotic dose is a frequent and avoidable cause of reduced drug effect.

  • Regulatory status: Sold as a dietary supplement in the United States and European Union, not a medicine. Manufacturers are not required to demonstrate efficacy before sale, and content accuracy is not verified pre-market.

  • Cost and accessibility: Inexpensive and widely available without prescription. Bisglycinate costs several times more per unit of elemental magnesium than oxide, but remains well under a dollar per day at typical doses.

Interaction with Foundational Habits

  • Sleep: Direct and modestly positive. Magnesium supports GABA tone and blunts NMDA excitation while the glycine component lowers core body temperature, both plausible sleep-onset routes. The bisglycinate trial by Schuster et al. dosed 30–60 minutes before bed. The effect is small and largest in people with low dietary magnesium.

  • Nutrition: Indirect and bidirectional. Magnesium-rich foods — leafy greens, legumes, nuts, seeds, whole grains, dark chocolate — carry the mortality signal that supplements do not. High alcohol intake, refined-carbohydrate diets and very high calcium doses all increase loss or compete for absorption. Dietary intake is tallied first when a supplemental dose is set.

  • Exercise: Direct but small. Sweat and urinary losses rise with training volume, so requirements increase. The meta-analysis by Wang et al. found no strength or power benefit in athletes with adequate magnesium status, with gains confined to deficient older adults. There is no evidence of blunted training adaptation.

  • Stress management: Indirect and unresolved. Stress hormones increase urinary magnesium excretion, and low magnesium is proposed to amplify stress reactivity in turn. The review by Boyle et al. found the human evidence mixed, and the bisglycinate trial found no change in perceived stress. Supplementation does not substitute for stress-reduction practice.

Monitoring Protocol & Defining Success

Before starting, the informative baseline is narrow: kidney filtration, blood magnesium, and the electrolytes magnesium depletion drags down with it. Blood magnesium alone is a poor status marker — it holds less than one percent of body stores and is defended tightly — so a normal value does not exclude depletion, and red blood cell magnesium is the better index where a laboratory offers it. Recording a week of home blood pressure and a fasting glucose value gives the two outcomes with the clearest quantified response something to be measured against. Ongoing monitoring is light in healthy adults: repeat blood magnesium, potassium, calcium and creatinine at 8–12 weeks, then every 6–12 months. Anyone on diuretics, proton pump inhibitors or with reduced kidney filtration warrants the earlier checkpoint and annual testing thereafter.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Serum magnesium 0.85–0.95 mmol/L (2.07–2.31 mg/dL) Only routinely available index of magnesium status Conventional reference range 0.7–1.1 mmol/L flags overt deficiency only; draw fasting and avoid a haemolysed (blood-cell-damaged) sample
Red blood cell magnesium 4.2–6.8 mg/dL Reflects stores inside cells, which serum does not Often abbreviated RBC magnesium, where RBC means red blood cell; not offered by every laboratory; most informative when paired with the serum value
Estimated glomerular filtration rate ≥90 mL/min/1.73 m²; ≥60 acceptable Kidneys clear all excess magnesium; the safety gate Abbreviated eGFR, a calculated measure of kidney filtration; derived from creatinine, ideally with cystatin C; recheck when a new kidney-affecting drug starts
Serum potassium 4.0–4.5 mmol/L Magnesium depletion causes potassium loss that will not correct without magnesium Conventional range 3.5–5.1 mmol/L; a stubborn low-normal value points at magnesium
Serum calcium (albumin-adjusted) 9.2–9.8 mg/dL Magnesium depletion suppresses parathyroid hormone and lowers calcium Best paired with parathyroid hormone; adjust for the blood protein albumin
Parathyroid hormone 15–35 pg/mL Detects the hormonal consequence of magnesium depletion Abbreviated PTH, the hormone that regulates blood calcium; conventional range extends to 65 pg/mL
25-hydroxyvitamin D 40–60 ng/mL Magnesium is a cofactor for every vitamin D activating enzyme Conventional sufficiency threshold is 30 ng/mL; measure before and after adding magnesium to vitamin D
Glycated haemoglobin ≤5.4% Tracks the glucose benefit where one exists Abbreviated HbA1c, an average of blood sugar over roughly three months; conventional cutoff 5.7%
Home blood pressure <120/80 mmHg The best-quantified benefit; needs its own baseline Average morning and evening seated readings across seven days rather than single clinic values

Qualitative markers worth tracking alongside the laboratory values:

  • Time taken to fall asleep, and whether it shortens within the first two weeks
  • Sleep continuity — number and duration of night wakings
  • Morning alertness, and specifically whether any residual drowsiness appears
  • Frequency of night-time leg cramps, eyelid twitching and palpitations
  • Stool consistency, which doubles as the practical dose ceiling
  • Subjective muscle tension and post-exercise soreness
  • Headache or migraine frequency for those who get them

Success is defined not by a rising blood magnesium number — which moves little — but by movement in whichever endpoint prompted use: shorter sleep onset, lower home blood pressure, fewer cramps or migraines, with stool consistency unchanged.

Emerging Research

  • Blood pressure trial in elevated systolic pressure: Brigham and Women’s Hospital is testing 480 mg/day magnesium glycinate against placebo in 120 adults over 12 weeks, with seated systolic and diastolic change as primary endpoints. NCT05690464 is active and no longer recruiting.

  • Add-on bisglycinate in major depression: The DReAM-BiG trial randomises 84 adults on stable antidepressants to 220 mg elemental magnesium as bisglycinate or placebo for eight weeks, with depression rating scale change as the primary endpoint plus serum glycine and neurotrophic factor measurement. NCT07633080 is recruiting.

  • Form-versus-form trial in athletes: UCLA plans to randomise 150 collegiate athletes to nightly magnesium glycinate (about 240 mg elemental), magnesium L-threonate or placebo for four weeks, measuring wearable-derived sleep efficiency. NCT07640685 would be the first head-to-head comparison of the two consumer forms.

  • Fibromyalgia trial: An 86-patient trial of oral magnesium in fibromyalgia not responding to standard treatment, using a validated impact questionnaire as the primary endpoint. NCT07585045 is recruiting and addresses a use with almost no controlled evidence.

  • Where the case could weaken: Bagheri et al. found dietary magnesium associated with lower mortality while supplemental intake showed nothing. Adequately powered supplementation trials with hard endpoints could confirm that magnesium-rich diets, not capsules, carry the longevity signal.

  • Where the case could strengthen: Costello et al. argue the 350 mg supplemental limit understates tolerability and should be raised, which would license higher-dose trials. They write from the Center for Magnesium Education and Research, a magnesium advocacy body, so the argument warrants independent replication.

  • Unresolved question of form: No trial has compared bisglycinate against another organic magnesium salt for a clinical endpoint. Until one does, the case for paying a premium over citrate rests on tolerability and on the 1994 isotope study by Schuette et al..

Conclusion

Magnesium bisglycinate is a magnesium salt bound to the amino acid glycine, sold on the promise of better absorption and a gentler effect on the bowel than cheaper forms. That tolerability advantage is real and is the strongest reason to choose it, though it rests on one small isotope study and on the chemistry rather than on head-to-head clinical trials.

What magnesium itself does is better established. Blood pressure falls, blood sugar control improves, sleep comes a little faster and mood scores improve — but almost entirely in people who started with low magnesium or an already-treated condition. In adults eating well, the same doses move very little. The mineral-rich diet, not the capsule, is what tracks with living longer in the population data, and that distinction is the single most important finding in this review.

The risks are narrow and mostly dose-driven: softened stools at the top of the range, and a genuine hazard only where kidney filtration is impaired. Magnesium also blocks the absorption of several common medicines when taken at the same time.

Evidence quality is uneven. Many trials are small, short and of moderate quality, and only one placebo-controlled trial has tested this particular form. Some of the argument for higher doses comes from a magnesium advocacy organisation and from companies selling the product, which does not make it wrong but does sit alongside it as an interest in the outcome.

Top - Benefits - Risks - Protocol